• Journal of the Institute of Electronics Engineers of Korea SD
• /
• v.40 no.6
• /
• pp.393-399
• /
• 2003

The current paper presents a new Mo-MPS rectifier using molybdenum as barrier metal to improve on the low forward voltage drop and power dissipation of the coventional Al-MPS and Pt-MPS rectifier. Electrical characteristics of the fabricated Mo-MPS rectifier are imvestigated compared with Al-MPS and Pt-MPS rectifier. At the same current level, the forward voltage drop of the Mo-MPS was reduced by 0.11V~0.24V compared to that of the conventional MPS rectifier. Accordingly, since the Power dissipation of a rectifier mostly depends on the forward current density and forward voltage drop, the Mo-MPS rectifier achieved improved power dissipation when compared to the conventional MPS rectifier. The reverse breakdown voltage of a Mo-MPS rectifier with 68% Schottky junction area was about 304y. Despite having a lower forward voltage drop than a conventional MPS rectifier, the Mo-MPS rectifier still exhibited a higher reverse breakdown voltage.

• Journal of mucopolysaccharidosis and rare diseases
• /
• v.3 no.1
• /
• pp.1-8
• /
• 2017

Mucopolysaccharidosis (MPS) type III, or Sanfilippo syndrome is a rare autosomal recessive lysosomal storage disorder. It is caused by a deficiency of one of four enzymes involved in the degradation of the glycosaminoglycan (GAG) heparan sulfate. The resultant cellular accumulation of heparan sulfate causes various clinical manifestations. MPS III is divided into four subtypes depending on the deficient enzyme: MPS IIIA, MPS IIIB, MPS IIIC and MPS IIID. All the subtypes show similar clinical features and are characterized by progressive degeneration of the central nervous system (CNS). Main purpose of the treatment for MPS III is to prevent neurologic deterioration. However, conventional enzyme replacement therapy has a limitation due to inability to cross the blood-brain barrier. Several experimental treatment options for MPS III are being developed.

• Environmental and Resource Economics Review
• /
• v.9 no.4
• /
• pp.597-619
• /
• 2000

Marketable permit system (MPS) is a economic incentive instrument that allows polluters to achieve static and dynamic efficiency, However, Korea's atmospheric regulations are primarily based upon command and control (CAC) system and partly upon economic incentive instruments, which fail to realize its relative effectiveness, Accordingly, an introduction of MPS has been recommended with the cost effectiveness analysis in numerous studies, The literature, however, did not consider the relationship between MPS and the existing regulations, which is a key factor for the successful introduction of MPS, This paper provides a set of principles to judge how the existing regulations are reconciled with the introduction of MPS, In addition, authors execute an empirical study to show MPS's cost effectiveness when regulators apply MPS in Ulsan area for the abatement of sulfur dioxide, The results suggest that the regulations such as fuel regulation should be excluded when implementing MPS, and a flexibility in legal and regulatory system is to be required in order to secure a successful implementation of MPS.

• Journal of mucopolysaccharidosis and rare diseases
• /
• v.1 no.1
• /
• pp.2-4
• /
• 2015

Though the rate of incidence of each rare disease, including mucopolysaccharidosis (MPS), is low, this is not the case if they are taken as a whole. Rare diseases often have genetic causes and vary in type. However, the signs and symptoms vary greatly by disease, making it difficult to make accurate diagnoses and conduct necessary research, which is why we believe it is a field that deserves more attention and research. It is important to establish an infrastructure of experts in each country and promote cooperation within the Asia-Pacific region in order to improve specialist training and communication. Given the need for a system of cooperation, the Asia Pacific MPS Network (APMN) was established by several MPS experts in South Korea, Japan, and Taiwan in January 2013. Thereafter, the Asia Pacific MPS Registry (APMR), an electronic remote data system, was established by the APMN. Then, the Association for Research of MPS & Rare Diseases (ARMRD), an academic society that supports research on MPS and other rare diseases, was established by President Dong-Kyu Jin in April in 2015. The main task of the ARMRD is to support APMN-related work. The ARMRD published a uniform guideline that reflects the characteristics and circumstances of local patients through the Korean MPS Expert Council. Now, the APMN, APMR, and the annual Korean MPS Symposium are supported by ARMRD. Organizations like the APMN and APMR are necessary because international cooperation and collaboration are needed to conduct clinical trials on those diseases. ARMRD members hope to encourage the interest of experts and researchers of MPS & rare diseases as well as active participation in the research and treatment of patients suffering from rare diseases, including MPS, to ultimately improve the quality of life of the patients as well as their families.

• Journal of The Korean Society of Inherited Metabolic disease
• /
• v.10 no.1
• /
• pp.59-66
• /
• 2010

Enzyme replacement of therapy (ERT) is one of the most promising therapeutic strategies for the treatment of lysosomal storage disorders. ERT is available in three types of Mucopolysaccharidosis (MPS): for MPS I (Aludrazyme$^{(R)}$), MPS II (Elaprase$^{(R)}$) and MPS VI (Naglazyme$^{(R)}$) patients who are over 5 years old. But recently, early diagnosis can be done by expert clinicians and even in prenatal case. We describe the case of ERT under 5 years old MPS patients. Up to June, 2010 in Samsung Medical Center, there are 6patients who were diagnosed as MPS and started ERT under 5 years old. 3 patients were MPS I, 3 patients were MPS II. 2 patient who was diagnosed as MPS I was female and others were male. Their age at diagnosis were 4 to 37month-old (4, 13, 16, 25, 27, 37 month-old) and they are now 9 to 60 month-old (9, 39, 32, 81, 60 month-old). The youngest patient was started ERT at 4 month-old and others were started at their 13 to 49 month-old (13, 29, 27, 28, 49 month-old). First manifested symptoms of patients were macrocephaly, kyphosis and coarse face appearance. Especially, in 2 of them, one was MPS I and the other was MPS II had elder brother with same disease. And the youngest one was diagnosed by the iduronate-2-sulfatase (IDS) gene analysis from chorionic villi sampling. His mother knew that she was a heterozygous carrier of IDS gene mutation because her younger brother died from MPS II. All of them confirmed as MPS by the enzyme assay in leukocytes and fibroblast skin culture. We started ERT with ${\alpha}$-L-iduronidase(Aldurazyme$^{(R)}$) to MPS I and did recombinant human iduronate-2-sulfatase (Elaprase$^{(R)}$) to MPS II patients as recommended dose as over 5 years old. But for MPS II patient who was 4 month old, we started ERT by recombinant human IDS (Elaprase$^{(R)}$) with reduced dose 0.1 mg/kg and increased dose every 2 weeks by 0.1mg/kg up to 0.5mg/kg IV infusion. During ERT, all patients had no adverse effects and the excretion of GAGs were decreased. We have evaluated other clinical symptoms such as liver/ spleen volume, heart function and neurologic evaluation. We describe a successful ERT to MPS I and MPS II patient under 5 years old without any adverse event. It indicates that ERT in young children are well tolerated and that it has several effects which may confer clinical benefits with long-term therapy.

• Journal of the Korea Society of Computer and Information
• /
• v.28 no.4
• /
• pp.143-150
• /
• 2023

As the use of mobile devices such as PDAs and smart-phones increases, the Mobile Payment System(MPS) is widely used as a new payment method. Accordingly, domestic and foreign MPS users can conveniently purchase or use the products and services they want, free from the constraints of time and space. In this situation, the study was to investigate how the perception of MPS value varies depending on the characteristics of MPS users(demographic characteristics, MPS usage characteristics), and to analyze whether the perception of MPS value ultimately has a significant effect on user satisfaction. To accomplish these research purposes, the study conducted a statistical analysis using a questionnaire for people with experience using MPS in Korea. The analysis results of the study could be useful in seeking ways to successfully spread of MPS at home and abroad and improve user satisfaction in the future.

• The Korean Journal of Pain
• /
• v.24 no.2
• /
• pp.100-104
• /
• 2011

Background: Myofascial pain syndrome (MPS) is a regional musculoskeletal pain disorder that is caused by myofascial trigger points. The objective of this study was to determine the prevalence of MPS among chronic back pain patients, as well as to identify risk factors and the outcome of this disorder. Methods: This was a prospective observational study involving 126 patients who attended the Pain Management Unit for chronic back pain between 1st January 2009 and 31st December 2009. Data examined included demographic features of patients, duration of back pain, muscle(s) involved, primary diagnosis, treatment modality and response to treatment. Results: The prevalence of MPS among chronic back pain patients was 63.5% (n = 80). Secondary MPS was more common than primary MPS, making up 81.3% of the total MPS. There was an association between female gender and risk of developing MPS ($x^2$ = 5.38, P = 0.02, O.R. = 2.4). Occupation, body mass index and duration of back pain were not significantly associated with MPS occurrence. Repeated measures analysis showed significant changes (P < 0.001) in Visual Analogue Score (VAS) and Modified Oswestry Disability Score (MODS) with standard management during three consecutive visits at six-month intervals. Conclusions: MPS prevalence among chronic back pain patients was significantly high, with female gender being a significant risk factor. With proper diagnosis and expert management, MPS has a favourable outcome.

• Journal of mucopolysaccharidosis and rare diseases
• /
• v.4 no.1
• /
• pp.11-13
• /
• 2018

In Malaysia, diagnosis and treatment of patients with mucopolysaccharidoses (MPS) is mainly localized at Hospital Kuala Lumpur, which is the national referral center for rare diseases. To date there are 83 patients diagnosed with MPS in our center, with MPS II being the commonest. The Malaysian National Medicines Policy second edition has a specific section on the orphan drugs which includes recombinant human enzyme for enzyme replacement therapy (ERT) in MPS. So far, National Pharmaceutical Regulatory Agency Malaysia has approved recombinant human enzyme for MPS types I (Loranidase), II (idursulfase), IVA (elosulfase alfa), and VI (Galsufase). Access to Idursulfase beta (another recombinant human enzyme for MPS II) and vestronidase alfa-vjbk (MPS VII) required special authorization on named patient basic. Currently there are 25 patients receiving ERT, 70% of the funding are from Ministry of Health (MOH), the remaining 30% are from various charitable funds and humanitarian programs. Thirteen newly diagnosed patients have to queue for an additional fund. Four patients have been treated with Hematopoietic stem cell transplant. MOH has also published guidelines regarding the patient selection criteria for ERT and treatment monitoring schedule.

• Journal of Korean Society of Environmental Engineers
• /
• v.34 no.7
• /
• pp.488-494
• /
• 2012

This study was conducted to determine the optimal ratio of sludges from milk processing industry (MPS), paper-mill industry (PMS) and night-soil treatment plant (NSS) for vermicomposting. Five different ratios, 0 : 80 : 20 (MPS-0), 25 : 60 : 15 (MPS-25), 50 : 40 : 10 (MPS-50), 75 : 20 : 5 (MPS-75), and 100 : 0 : 0 (MPS-100 : control) MPS : PMS : NSS by wet weight were tested in a small plot experiment. The experiment for each mixing ratio was performed for 2 weeks with the three replications. MPS-100 (100 : 0 : 0) only had the highest decomposition rate with 19.9%, followed by MPS-25, MPS-50, MPS-75 and MPS-0 with 19.5, 19.1, 17.6 and 16.7%, respectively. Except for MPS-100, Vermicomposting resulted in increase in ash, T-P, $NO_2{^-}-N$, $NO_3{^-}-N$, Mg, K, As, Cd and Cu, whereas moisture, VS (Volatile Substance), TKN (Total Kjeldahl Nitrogen), $NH_4{^+}-N$, Ca, Hg and Pb were lower in the final cast than the initial feed mixture. Meanwhile Zn showed very slight difference and Cr and Ni did not show any tendency between the feed mixture and the final cast. In the case of MPS-100, where the decomposition rate was the highest, all the heavy metals in the final cast except for Hg were increased. All the vermicomposts produced from five different mixing ratios of the vermicomposting sludges met the Korea Standard as by-product compost.

• Journal of Periodontal and Implant Science
• /
• v.48 no.1
• /
• pp.22-33
• /
• 2018

Purpose: The purpose of this study was to evaluate the efficacy of the modified plaque score (MPS) for assessing the oral hygiene status of periodontitis patients. Methods: A total of 116 patients were included in this study. After evaluation of the $L{\ddot{o}}e$ and Silness gingival index (GI), Silness and $L{\ddot{o}}e$ plaque index (PlI), O'Leary plaque control record (PCR), and MPS, patients were randomly assigned to either a conventional tooth brushing instruction (C-TBI) group (n=56) or a professional intraoral tooth brushing instruction (P-TBI) group (n=60). The MPS and clinical parameters were re-evaluated after scaling and a series of root planing. The convergent validity of MPS with the PlI and PCR was assessed. The measurement time for MPS and PCR was compared according to the proficiency of the examiner. Results: After root planing, the GI, PlI, PCR, and MPS improved from their respective baseline values in both groups. Three different plaque indices including the MPS, showed significant differences between the C-TBI group and the P-TBI group after root planing. The MPS showed significant concurrence with the PCR and PlI. The mean time for PCR measurement was $2.76{\pm}0.71$ times longer than that for MPS measurement after 2 weeks of training. Conclusions: MPS seems to be a practical plaque scoring system compared with the PlI and PCR. These findings suggest that repetitive plaque control combined with an easily applicable plaque index (MPS) may facilitate more effective oral hygiene education and improved periodontal health.